RecruitingNot ApplicableNCT05258396

Exploring Cortical Remyelination in Children With Multiple Sclerosis


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

40 participants

Start Date

Aug 11, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.


Eligibility

Min Age: 12 YearsMax Age: 18 Years

Inclusion Criteria9

  • age between 12 years old and 18 years old
  • RR-MS defined by 2017 McDonald criteria
  • no relapse the last 4 weeks
  • no methylprednisolone or prednisolone the last 4 weeks.
  • affiliated to the social security system
  • signature of the consent by the 2 holders of parental authority
  • age between 12 years old and 18 years old
  • absence of any neurological
  • signature of the consent by the 2 holders of parental authority

Exclusion Criteria3

  • Parental rejection
  • Contre-indication of brain MRI: pace maker, tatoo of the face, claustrophobia….
  • Pregnancy, copper intrauterine device

Interventions

OTHERMRI without injection of contrast product

MRI without injection of contrast product


Locations(3)

Service de Neurologie Pédiatrique, Hôpital du Kremlin Bicêtre

Le Kremlin-Bicêtre, France

CIC Neurosciences - Pitié Salpêtrière

Paris, France

Service de Neurologie, GH Pitié Salpêtrière

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05258396